# New Obesity clinical trials: 1,940 posted since Nov 2024

Updated November 9, 2026.

1,940 clinical studies in obesity were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 527 have an industry sponsor and 1,128 are recruiting or about to. The newest, NCT07926152, was posted on November 9, 2026: Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes (German Diabetes Center).

## The full list

New Obesity clinical trials: 1,940 rows for $97, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 107 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/obesity

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 1,940
- Industry sponsored: 527
- Recruiting or not yet: 1,128
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 1,940, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926152 | Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes | German Diabetes Center | Not applicable | Not yet recruiting | Type 2 Diabetes (T2DM), Obesity & Overweight, Sarcopenia | 94 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926152) |
| November 9, 2026 | NCT07925684 | Determination of ED90 of Remimazolam Besylate Combined With Alfentanil for Gastroscopy Sedation in Obese Patients | Jianbo Wu | Not applicable | Recruiting | Procedural Sedation and Analgesia, Obesity & Overweight | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925684) |
| November 9, 2026 | NCT07925294 | The Impact of Myofunctional Therapy on Children With Sleep Apnea and Obesity | Université Catholique de Louvain | Not applicable | Not yet recruiting | Obstructive Sleep Apnea (OSA) and Obesity | 62 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925294) |
| November 9, 2026 | NCT07924761 | A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living... | Kailera | Phase 1 | Not yet recruiting | Overweight or Obesity | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924761) |
| November 9, 2026 | NCT07924618 | Ocular Changes in Patients Using Tirzepatide or Semaglutide | Istanbul University | Observational | Recruiting | Type 2 Diabetes Mellitus, Obesity | 40 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924618) |
| November 9, 2026 | NCT07924436 | Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes | Pamukkale University | Not applicable | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 30 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924436) |
| November 9, 2026 | NCT07924267 | A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic... | EktaH | Phase 1 | Completed | Obesity & Overweight, Overweight (BMI \> 30) | 120 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924267) |
| November 6, 2026 | NCT07923513 | Compulsive Eating and Brain's Reward System in Different Pathologies | University Hospital, Clermont-Ferrand | Not applicable | Not yet recruiting | PARKINSON DISEASE (Disorder), Bipolar 1 Disorder, Obesity (BMI\>30) | 150 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923513) |
| November 6, 2026 | NCT07923240 | Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional... | Research Center of Neurology, Russia | Phase 4 | Active not recruiting | Metabolic Abnormalities, Obesity & Overweight, Cerebral Atherosclerosis, Cerebrovascular Disease | 30 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923240) |
| November 6, 2026 | NCT07922798 | A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy... | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Not yet recruiting | Overweight , Obesity | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922798) |
| November 6, 2026 | NCT07922694 | Obesity-Related Indices and Albuminuria in Type 2 Diabetes | Assiut University | Observational | Not yet recruiting | Obesity and Diabetes Mellitus, Type 2, Albuminuria | 349 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922694) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | China, India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 6, 2026 | NCT07922005 | Lifestyle Interventions and Genetic Scores for Weight Management | National and Kapodistrian University of Athens | Not applicable | Completed | Overweight , Obesity | 198 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922005) |
| November 6, 2026 | NCT07921940 | Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy | Medical University of Vienna | Not applicable | Active not recruiting | Obesity & Overweight, Gestational Diabetes Mellitus (GDM), Insulin Resistance, Maternal Obesity Complicating Pregnancy | 40 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921940) |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921316) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 5, 2026 | NCT07919158 | Impact of Dyslipidemia on Metabolic Health of Adults With Overweight/Obesity (IDOM): A Study at the San Raffaele Hospital Center for... | Rovere Querini Patrizia | Observational | Active not recruiting | Dyslipidemia, Obesity & Overweight | 900 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919158) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| November 4, 2026 | NCT07916753 | Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition | Fondation Net-Care.ch | Not applicable | Not yet recruiting | Hypertension, Diabetes Mellitus, Type 2, Obesity | 1,600 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916753) |
| November 4, 2026 | NCT07916194 | A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants | Beijing QL Biopharmaceutical Co.,Ltd | Phase 1 | Not yet recruiting | Overweight, Obesity | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916194) |
| November 4, 2026 | NCT07915986 | Brain Dopamine Dynamics in Obesity | Yale University | Phase 1 | Not yet recruiting | Obesity | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915986) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Not yet recruiting | Obesity, Overweight | 108 | Singapore, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 3, 2026 | NCT07913685 | The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight... | Medical University of Bialystok | Phase 4 | Completed | Obesity & Overweight | 83 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913685) |
| November 2, 2026 | NCT07911514 | A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Not yet recruiting | Healthy Participants | 60 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911514) |
| November 2, 2026 | NCT07911046 | Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity | Erin Mauney | Observational | Not yet recruiting | Pediatric Obesity, Obesity | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911046) |
| November 2, 2026 | NCT07910747 | Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in... | University of Sao Paulo | Not applicable | Not yet recruiting | Obesity (Disorder), Inflammation | 60 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910747) |
| November 2, 2026 | NCT07909889 | Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer | Aarhus University Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer), Obesity | 32 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909889) |
| November 2, 2026 | NCT07909772 | Effects of a Multispecies Probiotic on Metabolic, Liver, and Gut Health | University of Bari | Not applicable | Completed | Metabolic-Associated Steatotic Liver Disease, Diabetes (DM), Obesity & Overweight | 56 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909772) |
| November 2, 2026 | NCT07908940 | Changes in Body Composition Following Pharmacological Treatment for Obesity. | Hospital San Carlos, Madrid | Observational | Enrolling by invitation | Obesity (BMI Equal to or \>30), Weight Regain After Bariatric Surgery | 116 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908940) |
| November 2, 2026 | NCT07908823 | ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation | Affiliated Hospital to Academy of Military Medical Sciences | Not applicable | Not yet recruiting | Obesity & Overweight | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908823) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 30, 2026 | NCT07907029 | Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight... | Guangdong Provincial Hospital of Traditional Chinese Medicine | Not applicable | Not yet recruiting | Overweight, Obesity | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907029) |
| October 29, 2026 | NCT07905274 | Sarcopenia Risk in Obese T2DM Patients | Bandırma Onyedi Eylül University | Observational | Not yet recruiting | Sarcopenia, Obesity Type 2 Diabetes Mellitus | 150 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905274) |
| October 29, 2026 | NCT07904663 | The Sleep and Weight Study | NYU Langone Health | Not applicable | Not yet recruiting | Obesity | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904663) |
| October 29, 2026 | NCT07903025 | Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity | Axomove | Not applicable | Not yet recruiting | Obese Adults | 184 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903025) |
| October 29, 2026 | NCT07902895 | Intrathoracic Sleeve Migration (Sliding Hiatal Hernia) One Year or More After Laparoscopic Sleeve Gastrectomy | Kasr El Aini Hospital | Observational | Completed | Hiatal Hernia, Gastroesophageal Reflux Disease, Obesity, Postoperative Complications | 61 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902895) |
| October 29, 2026 | NCT07902752 | Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs | George Washington University | Phase 2 | Not yet recruiting | Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902752) |
| October 28, 2026 | NCT07902232 | Gestational Weight Loss and Restrictive Weight Gain in Maternal Obesity: A Target Trial Emulation | Shanghai First Maternal and Infant Health Hospital affiliated to Tongji University Medical School | Observational | Completed | Pregnancy, Obesity, Gestational Hypertension, Gestational Weight Gain | 205,636 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902232) |
| October 28, 2026 | NCT07901777 | Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity | Yuzuncu Yil University | Observational | Recruiting | Obesity & Overweight | 200 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901777) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 28, 2026 | NCT07900178 | Sustaining Health After an Intensive Weight-loss Pro-gramme | Copenhagen University Hospital, Hvidovre | Observational | Enrolling by invitation | Obesity & Overweight, Weight Loss, Weight Management in Adult Patients With Obesity or Overweight | 150 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900178) |
| October 28, 2026 | NCT07900074 | Mechanisms of Weight Loss: Tirzepatide vs Semaglutide | McMaster University | Phase 4 | Recruiting | Obesity (Disorder) | 80 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900074) |
| October 27, 2026 | NCT07898267 | Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity | Second Affiliated Hospital of Nanchang University | Not applicable | Not yet recruiting | Obesity & Overweight | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898267) |
| October 27, 2026 | NCT07897890 | Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care | Indiana University | Not applicable | Completed | Obesity & Overweight, Breast Cancer | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897890) |
| October 27, 2026 | NCT07897682 | Impact of Significant Surgical Reduction of Adipose Tissue on Plasma Levels and Genetic Expression of Adipokines Associated With Ischemic... | King Edward Medical University | Not applicable | Not yet recruiting | Obesity & Overweight, Obesity Type I and II | 212 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897682) |
| October 27, 2026 | NCT07897383 | Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity | University Hospital, Gentofte, Copenhagen | Phase 1/2 | Not yet recruiting | Obesity & Overweight | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897383) |
| October 27, 2026 | NCT07897305 | Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients | Beijing Anzhen Hospital | Not applicable | Not yet recruiting | Atrial Fibrillation (AF), Ablation Treatment, Obesity & Overweight, Mazdutide | 700 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897305) |
| October 26, 2026 | NCT07895563 | A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control | MNnutra | Not applicable | Active not recruiting | Overweight, Obesity, Weight Management, Appetite Control | 170 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895563) |
| October 26, 2026 | NCT07894692 | Association of WWI With Difficult Intubation | Cairo University | Observational | Completed | General Anesthesia; Tracheal Intubation | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894692) |
| October 26, 2026 | NCT07893743 | Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding. | University Hospital, Gentofte, Copenhagen | Not applicable | Recruiting | Obesity & Overweight | 20 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893743) |
| October 26, 2026 | NCT07893717 | Motivational Interviewing Intervention for Families With Overweight and Obesity | Universidad Autonoma de Baja California | Not applicable | Active not recruiting | Obesity & Overweight | 120 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893717) |
| October 26, 2026 | NCT07893457 | Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity | Mayo Clinic | Phase 4 | Not yet recruiting | Obese Adults | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893457) |
| October 23, 2026 | NCT07893249 | Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences | Not applicable | Not yet recruiting | Physical Inactivity, Overweight, Obesity | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893249) |
| October 23, 2026 | NCT07893106 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants... | Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Chronic Weight Management | 86 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893106) |
| October 23, 2026 | NCT07893093 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants... | Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Chronic Weight Management | 144 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893093) |
| October 23, 2026 | NCT07891975 | Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy | University of Lahore | Not applicable | Completed | Liver Biomarkers, Glucose, Lipid Profiles | 102 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891975) |
| October 23, 2026 | NCT07891156 | Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2/3 | Recruiting | Type 1 Diabetes, Overweight , Obesity | 40 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891156) |
| October 22, 2026 | NCT07890870 | A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | iBio, Inc. | Phase 1 | Not yet recruiting | Obesity & Overweight | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890870) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | Argentina, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 22, 2026 | NCT07889570 | A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression | Evolv | Not applicable | Completed | Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression, Weight Management | 98 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889570) |
| October 22, 2026 | NCT07889453 | Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide | LMC Diabetes & Endocrinology Ltd. | Observational | Active not recruiting | Obesity, Type 2 Diabetes (T2D) | 650 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889453) |
| October 21, 2026 | NCT07886788 | Study of Grape Consumption in Adaptation to Seasonal Photoperiod | University Rovira i Virgili | Not applicable | Active not recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight, Obesity & Overweight | 46 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886788) |
| October 21, 2026 | NCT07884994 | HUGO-SLEEVE: Evaluating the Feasibility of Robotic Sleeve Gastrectomy With a New Platform | Universitätsklinikum Hamburg-Eppendorf | Not applicable | Recruiting | Obesity (BMI \> 35), Obesity (BMI \> 35) and Diabetes Mellitus, Obesity (BMI \> 35) and Dyslipemia, Obesity (BMI \> 35) and... | 50 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884994) |
| October 21, 2026 | NCT07884903 | Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks | Shanxi Bethune Hospital | Observational | Not yet recruiting | Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)... | 25,974 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884903) |
| October 20, 2026 | NCT07884058 | IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity | University of Yaounde 1 | Phase 2 | Not yet recruiting | Obesity & Overweight | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884058) |
| October 20, 2026 | NCT07883031 | Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity | University of North Alabama | Not applicable | Completed | Overweight (BMI \> 25), Obesity & Overweight | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883031) |
| October 20, 2026 | NCT07882654 | A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN... | EktaH | Phase 2 | Not yet recruiting | Obesity / Overweight, Obesity (BMI Equal to or \>30) | 31 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882654) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Not yet recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | Singapore, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 19, 2026 | NCT07881770 | Semaglutide Health Outcomes and Patient Adherence in Australia | Novo Nordisk A/S | Observational | Not yet recruiting | Overweight, Obesity | 10,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881770) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | Argentina, China, Germany, India, Japan, Puerto Rico, South Korea, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 19, 2026 | NCT07880847 | MORPH-A - Multidisciplinary Obesity Rehabilitation & Psychophysical Health and Awareness | Istituti Clinici Scientifici Maugeri SpA | Not applicable | Recruiting | Obesity | 34 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880847) |
| October 19, 2026 | NCT07880717 | Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years | Mahidol University | Observational | Recruiting | Diabete Mellitus, Dyslipidaemia, Chronic Kidney Disease, Psychiatric Disorder, Hypertension, Hypothyroidism, Smoking... | 93 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880717) |
| October 19, 2026 | NCT07880444 | Effects of Daily Avocado Consumption on Sleep and Skin Health in Postmenopausal Females | San Diego State University | Not applicable | Not yet recruiting | Poor Sleep Quality | 74 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880444) |
| October 16, 2026 | NCT07878299 | Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Observational | Recruiting | Lipedema, Obesity, Body Mass Index, Bioelectrical Impedance Analysis | 200 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878299) |
| October 16, 2026 | NCT07877090 | Frontal EEG Dynamics During Anesthesia in Patients With Obesity and Normal Weight | Duzce University | Observational | Recruiting | Obesity (BMI\>30), General Anesthesia | 60 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877090) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 15, 2026 | NCT07876531 | A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or... | Pfizer | Phase 1 | Recruiting | Overweight and/or Obesity, Healthy Participants | 144 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876531) |
| October 15, 2026 | NCT07876518 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity | Pfizer | Phase 1 | Not yet recruiting | Overweight and/or Obesity | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876518) |
| October 15, 2026 | NCT07875530 | VC-AF vs FCV in Obese Patients Undergoing Laparoscopic Surgery | Kocaeli University | Observational | Recruiting | Anesthesia, Mechanical Ventilation, Obesity | 78 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875530) |
| October 15, 2026 | NCT07874945 | Peripheral Vascular Effects of Insulin in Obesity | University of Missouri-Columbia | Early phase 1 | Not yet recruiting | Obesity (BMI\>30), Insulin Resistance | 64 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874945) |
| October 15, 2026 | NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sarcoma,Soft Tissue | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874828) |
| October 15, 2026 | NCT07874633 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight | 432 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874633) |
| October 14, 2026 | NCT07874399 | Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal Women | Gazi University | Not applicable | Not yet recruiting | Obesity (BMI Equal to or \>30), Postmenopausal Symptoms, Sleep Quality | 40 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874399) |
| October 14, 2026 | NCT07873762 | Effects of a 12-Week Individualized Energy-Restricted Diet on Perceived Stress and Serum Cortisol in Adults With Overweight or Obesity | Acibadem University | Not applicable | Completed | Obesity & Overweight | 30 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873762) |
| October 14, 2026 | NCT07873645 | Study of UBT37034 Injection | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Overweight , Obesity | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873645) |
| October 14, 2026 | NCT07872904 | FutureShape Family | Signe Torekov | Phase 4 | Recruiting | Obesity, Overweight | 400 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872904) |
| October 13, 2026 | NCT07872605 | Structured Perioperative Nursing Education and Short-Term Outcomes After Metabolic Bariatric Surgery | General Committee of Teaching Hospitals and Institutes, Egypt | Not applicable | Completed | Obesity, Morbid, Bariatric Surgery Candidate, Obesity | 86 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872605) |
| October 13, 2026 | NCT07871994 | Body Mass Index and Outcomes of Ultrasound-Guided Infraclavicular Brachial Plexus Block | Ankara City Hospital Bilkent | Observational | Not yet recruiting | Obesity (BMI\>30) | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871994) |
| October 13, 2026 | NCT07871565 | Time-Restricted Eating With or Without Energy Restriction in Dyslipidemic Women With Owerweight or Obesity | Acibadem University | Not applicable | Completed | Dyslipidemia, Obesity & Overweight | 56 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871565) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 13, 2026 | NCT07870668 | Intermittent Phentermine for Obesity and Body Composition | OSCAR MANUEL TORRES FALCON | Phase 4 | Completed | Obesity & Overweight | 600 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870668) |
| October 13, 2026 | NCT07870538 | A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge... | Universitaire Ziekenhuizen KU Leuven | Phase 4 | Recruiting | Obesity & Overweight | 96 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870538) |
| October 13, 2026 | NCT07869758 | Gastric On in Obesity Management: Evaluation of the Safety and Efficacy of the 6-Month Gastric Balloon (Prospective) | Rigicon, Inc. | Not applicable | Completed | Obesity & Overweight | 42 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869758) |
| October 9, 2026 | NCT07869472 | Post-exercise Blood Pressure With Inorganic Nitrate | University of Virginia | Not applicable | Not yet recruiting | Obese Individuals, Central Adiposity | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869472) |
| October 9, 2026 | NCT07869355 | BRE-13: Mediterranean Diet | University of Illinois Chicago | Not applicable | Not yet recruiting | Dietary Assessment, Dietary and Lifestyle Behaviour Change, Dietary Behavior, Metabolic Health, Obesity, Lifestyle... | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869355) |
| October 9, 2026 | NCT07869277 | Obesity and Clinical and Cytokine Responses to Periodontal Therapy | Emine Çifcibaşı | Not applicable | Completed | Periodontitis, Obesity (Body Mass Index \>30 kg/m2) | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869277) |
| October 9, 2026 | NCT07868978 | Radial Artery Dimensions and the Effect of Anaesthetic Induction in Morbid Obesity | Hilal Subaşı Artıran | Not applicable | Completed | Obesity, Morbid Catheterization, Peripheral | 76 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868978) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Novo Nordisk A/S | 76 | November 5, 2026 |
| Eli Lilly and Company | 54 | November 4, 2026 |
| Cairo University | 28 | October 26, 2026 |
| Pfizer | 26 | November 5, 2026 |
| Amgen | 25 | November 6, 2026 |
| AstraZeneca | 20 | November 6, 2026 |
| Shanghai Minwei Biotechnology Co., Ltd | 14 | September 17, 2026 |
| Hoffmann-La Roche | 13 | November 5, 2026 |
| Mayo Clinic | 11 | October 26, 2026 |
| Boehringer Ingelheim | 10 | October 2, 2026 |
| University of Alabama at Birmingham | 10 | September 18, 2026 |
| BrightGene Bio-Medical Technology Co., Ltd. | 10 | February 3, 2026 |
| Kailera | 9 | November 9, 2026 |
| Pamukkale University | 9 | November 9, 2026 |
| Assiut University | 9 | November 6, 2026 |
| Beijing QL Biopharmaceutical Co.,Ltd | 9 | November 4, 2026 |
| Pennington Biomedical Research Center | 9 | September 22, 2026 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 9 | September 8, 2026 |
| Gan & Lee Pharmaceuticals. | 9 | August 25, 2026 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 8 | November 6, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 952 | November 9, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 373 | November 9, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 205 | November 9, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 144 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 141 | November 2, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 81 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 23 | October 27, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 17 | October 15, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 4 | October 23, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 566 | November 9, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 275 | November 9, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 163 | November 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 111 | November 5, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 100 | November 5, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 83 | November 5, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 82 | November 9, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 78 | November 5, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 68 | November 6, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 68 | November 5, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 66 | November 5, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 55 | November 5, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 53 | October 29, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 50 | October 28, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 47 | November 5, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 47 | November 5, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 43 | October 19, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 42 | November 5, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 39 | November 6, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 38 | October 28, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 37 | November 5, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 36 | November 5, 2026 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 35 | November 5, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 28 | November 5, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 26 | September 8, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).